FDA Grants Fast Track Designation for Cocrystal Pharma's Norovirus Antiviral CDI-988
COCP sits 40% above its 52-week low of $0.859.
Summary
Cocrystal Pharma received FDA Fast Track designation for its norovirus antiviral, CDI-988, which could accelerate development and regulatory review for a critical pipeline candidate.
Key Events · Product Development and Regulatory · COCP
-
FDA Fast Track Designation
The U.S. Food and Drug Administration (FDA) granted Fast Track designation to CDI-988, Cocrystal Pharma's oral antiviral candidate for norovirus infection.
-
Accelerated Development Potential
This designation is expected to facilitate accelerated development and expedite the regulatory review process for CDI-988, which is the first oral antiviral candidate for norovirus.
-
Addresses Unmet Medical Need
The FDA's decision highlights the potential of CDI-988 to treat a serious condition and address the significant unmet medical need for norovirus infection, which causes an estimated 685 million global cases annually.
-
Ongoing Clinical Study
A Phase 1b norovirus challenge study for CDI-988 is currently underway at Emory University School of Medicine to evaluate its efficacy in preventing and treating norovirus infection.
Analysis · COCP · Life Sciences
This designation is a significant positive development for Cocrystal Pharma, especially following its recent going concern warning and setback in its Influenza A program. The FDA's Fast Track status for CDI-988, an oral antiviral for norovirus, acknowledges the drug's potential to address a serious condition with unmet medical needs. This designation is crucial as it facilitates expedited development and regulatory review, potentially accelerating the path to market for a key pipeline asset. For a clinical-stage company facing financial challenges, this regulatory milestone provides a much-needed positive catalyst and a clearer path towards potential future revenue generation.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COCP was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.1M. The 52-week trading range was $0.86 to $2.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.